Abstract
Integrated testing for TB and COVID-19 may help find those TB patients who are not accessing care in the context of the COVID-19 pandemic. Some molecular platforms with assays for both diseases are already commercially available; however, integrated testing approaches need to be systematically evaluated to ensure their appropriate implementation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 162-166 |
| Number of pages | 5 |
| Journal | Med |
| Volume | 3 |
| Issue number | 3 |
| DOIs |
|
| State | Published - Mar 11 2022 |
| Externally published | Yes |
ASJC Scopus subject areas
- General Medicine